DICE — Dice Therapeutics Income Statement
0.000.00%
Last trade - 00:00
HealthcareSpeculativeMid Cap
- $2.27bn
- $1.72bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 5.78 | 0.863 | 1.13 | 0 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Unusual Expense / Income | ||||
Total Operating Expenses | 19.3 | 24.6 | 48.7 | 88.4 |
Operating Profit | -13.5 | -23.7 | -47.6 | -88.4 |
Total Net Non Operating Interest Income / Expense | ||||
Total Net Non Operating Interest Income / Expense | ||||
Other Net Non Operating Costs | ||||
Net Income Before Taxes | -12.9 | -23.7 | -49 | -83.9 |
Net Income After Taxes | -12.9 | -23.7 | -49 | -83.9 |
Net Income Before Extraordinary Items | ||||
Net Income | -12.9 | -23.7 | -49 | -83.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -12.9 | -23.7 | -49 | -83.9 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -0.334 | -0.653 | -1.28 | -2.12 |
Dividends per Share |